Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Treasury Shares (2018 - 2025)

Revolution Medicines has reported Treasury Shares over the past 8 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Treasury Shares at $3.9 million for Q4 2025, up 36.56% from a year ago — trailing twelve months through Dec 2025 was $3.9 million (up 36.56% YoY), and the annual figure for FY2025 was $3.9 million, up 36.56%.
  • Treasury Shares for Q4 2025 was $3.9 million at Revolution Medicines, up from $3.8 million in the prior quarter.
  • Over the last five years, Treasury Shares for RVMD hit a ceiling of $3.9 million in Q4 2025 and a floor of $272.0 in Q4 2022.
  • Median Treasury Shares over the past 5 years was $1.6 million (2022), compared with a mean of $1.8 million.
  • Biggest five-year swings in Treasury Shares: tumbled 99.97% in 2023 and later skyrocketed 1102504.81% in 2024.
  • Revolution Medicines' Treasury Shares stood at $5793.0 in 2021, then crashed by 95.3% to $272.0 in 2022, then increased by 6.99% to $291.0 in 2023, then surged by 979319.93% to $2.9 million in 2024, then soared by 36.56% to $3.9 million in 2025.
  • The last three reported values for Treasury Shares were $3.9 million (Q4 2025), $3.8 million (Q3 2025), and $3.8 million (Q2 2025) per Business Quant data.